


# **The Miracle of EM-X Therapy in Breast Cancer.**

**Professor Khalida Usmani**


**M.B.B.S, M.D, F.R.C.S**

**Founder Cancer Research Foundation of Pakistan  
President, World Institute of Ecology & Cancer  
(Asia Chair)**




# **Risk Factors (Breast Cancer)**

- **Environmental**
  - **Chemicals**
  - **Pesticides**
  - **Insecticides**
- **Air, Water & Food Pollution causing: Carcinogenesis**
- **Multiparity (Average of 5 Childrens)**
- **Malnourishment**
- **Prolonged Lactation (Average of 18 Months)**
- **Fibrocystic Disease of Breast**




# **EMX - Antioxidant**

- ⊕ Increases T cell Population**
- ⊕ Immune Modulation**
- ⊕ Resistance to Disease**




# Dosage (EMX)

- **Group I** : **5-10 ml/Day**
- **Group II** : **10-20ml/Day**
- **Group III** : **No EMX**  
**(Control)**




# Investigations & Diagnosis

- **Mammography**
- **F.N.A**
- **True Cut N. Biopsy**




# Subjects & Methods

- **Group I : EMX Treated from Day I**
- **Group II : Metastatic Disease EMX Given**
- **Group III : Locally Advanced, EMX Given**
- **Group IV : Control- No EMX**





# **EM-X Therapy in Breast Cancer**

- 1<sup>st</sup> Phase : 1997 – 1999**
- 2<sup>nd</sup> Phase : 1999 – 2001**
- 3<sup>rd</sup> Phase : 2001 – 2003**
- 4<sup>th</sup> Phase : 2003 - 2006**




# Number of Cases







# Present Study

- **Age Range:**
  - 20 - 77 Years  
(Majority of Patients) 35 – 45 Years
- **Mostly Pre-menopausal**
- **Pregnant & Lactating - 14%**
- **Multiparous - 97 %**



# Improvement in Patients






# **Present Study**


- **EMX Started on Day 1 Before surgery**
- **No Mortality Due to CA Breast in g-I**


**(Mastectomy performed by Professor Usmani)**



# Mortality within 2 years of group 2 & 3


- EMX: 3 out of 55
- Control: 4 out of 9





# **Post Operative Observations:**


- **No Undue Pain or Discomfort.**
- **Emotional Stability.**
- **Good Appetite.**
- **Improved Vitality.**
- **Discharged from Hospital  
in 4-5 Days.**



## Group II

● Metastatic disease patients


- Bone Secondaries.
- Pleural Effusion or Lung Mets.
- Liver Metastases.




CENTRE FOR NUCLEAR MEDICINE, LAHORE  
KHALIDA SAFDAR 12170/01 Skeletal 2001.10.16

PATIENT NAME : KHALIDA SAFDAR  
PATIENT ID : 12170/01  
BIRTH DATE : 16-OCT-1961

INSTITUTE : CENTRE FOR NUCLEAR MEDICINE, LAHORE  
PROTOCOL : WHOLE BODY DUAL INTENSITY  
ACQ. DATE : 16-OCT-2001






PATIENT NAME : KHALIDA SAFDAR  
PATIENT ID : 14938/02  
ACQ. DATE : 19-DEC-2002


INSTITUTE : CENTRE FOR NUCLEAR MEDICINE, LAHORE  
PROTOCOL : LIVER SCAN

Posterior

Rt. Lateral


Anterior






# **EM-X Treated Patients**

- **Enhanced Work Status**
- **Improved Emotional Stability**
- **Improved Appetite**
- **Reduced Symptoms of  
Breathlessness & Pain**



# Conclusion

- ➊ Improved Immune Status ↑
- ➋ Relief in Symptomatology ↓
- ➌ Improved Work Status ↑
- ➍ Emotional Well Being ↑
- ➎ Improves Quality of Life ↑
- ➏ Longer Survival Time in all Groups receiving EMX



## **Conclusion.....cont.**

- **When Combined with Standard Treatment (Chemo + DXT +H.T)**
- **No Pyogenic or Fungal Infections**
- **Longer Disease Free Interval**
- **Cure**

